| Small agents |
HES 200/0.5 |
HES polymer |
Dexamethasone (DXM) |
No |
Targeted transport of DXM to NPCs |
81
|
| HES 200 |
HES polymer |
Monophosphoryl lipid A (MPLA) |
No |
Enhanced the uptake and phagocytosis |
82
|
| Not precisely |
HES polymer |
Diclofenac sodium (DS) |
SD rats |
Reduced dosage and frequency of administration of DS |
83
|
| HES 200/0.5 |
HES–PLLA |
Octenidine |
No |
Inhibited the enzymatic degradation |
84
|
| HES 20/0.5 |
HES–SS–DOX conjugate |
Indocyanine green (ICG) |
H22 tumor-bearing mice |
Highly efficient anti-tumor performance with ICG |
85
|
| HES 130/0.4 |
HES–OA conjugate |
Indocyanine green (ICG) |
H22 tumor-bearing mice |
Enhanced ICG stability, PDT synergistic antitumor effect |
86
|
| HES 130/0.4 |
Gal-HES–PCL |
Doxorubicin (DOX) and indocyanine green (ICG) |
H22 tumor-bearing mice |
Chemo/photothermal combination therapies |
87
|
| HES 25/0.5 |
HES–PDA |
Doxorubicin (DOX) |
H22 tumor-bearing mice |
Improved antitumor efficacy |
88
|
| HES 70/0.5 |
HES-g-PLA copolymers |
Doxorubicin (DOX) |
H22 tumor-bearing mice |
Effectively delivery of DOX |
89
|
| HES 130/0.4 |
iRGD–HES–SS–C18 |
Doxorubicin (DOX) |
No |
Enhanced cellular uptake and antitumor efficacy |
91
|
| HES 70/0.5 |
HES–PLA |
Doxorubicin (DOX) and LY2157299 (LY) |
4T1 cell in zebrafish |
Simultaneously suppress primary tumor and distant metastasis |
92
|
| HES 200 |
HES NCs |
Folic acid (FA) |
No |
Specific cellular uptake into HeLa cells |
93
|
| Biomolecules |
HES 130/0.4 |
HES–(P(EG)6 MA) polymer |
No |
No |
A delivery system for the controlled release of proteins |
94
|
| HES 130 |
HES–HEMA |
Lysozyme |
No |
Controlled release |
95
|
| HES 422/0.76 |
AcHES–PLGA |
Insulin |
Diabetic animal model |
Sustained release of proteins |
96
|
| HES 130/0.4 |
HES |
Bovine serum albumin (BSA) |
No |
Enhanced immune responses |
97
|
| HES 70/0.5 |
HES–PEI copolymers |
Plasmid pCMVluc (pDNA) |
No |
The shielding and controlled deshielding of DNA polyplexes |
98
|
| HES 200/0.5 |
HES NCs |
Cytokine interleukin-2 (IL-2) |
Wild-type C57BL/6 mice |
Direct and specifc target to human and murine T cells |
99
|
| HES 200/0.45 |
HES NCs |
(Oligo)mannose |
No |
Targeted delivery to dendritic cells |
100
|
